Open AccessPersonalized therapy: can it tame the COVID-19 monster?
Author(s) -
Mohd Arish,
Farha Naz
Publication year - 2021
Publication title -
personalized medicine
Language(s) - English
Resource type - Journals
eISSN - 1744-828X
pISSN - 1741-0541
DOI - 10.2217/pme-2021-0077
Subject(s) - medicine , personalized medicine , covid-19 , pandemic , adverse effect , clinical trial , intensive care medicine , bioinformatics , virology , disease , biology , outbreak , infectious disease (medical specialty)
SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-19 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-19 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.